ALBUQUERQUE, N.M., March 21 /PRNewswire/ -- Exagen Diagnostics, Inc., an emerging leader in the rapid identification and productization of practical, genomic markers for prognostic testing, today announced that Thomas Williams, M.D., joined the company as special advisor for molecular pathology. Dr. Williams will provide Exagen executives with scientific and market-based counsel on unmet needs in pathology. Dr. Williams is vice chairman, department of pathology, at the University of New Mexico School of Medicine. In addition, he serves as director of the Genetics and Cytometry Division at TriCore Reference Laboratories, a regional medical laboratory affiliated with the University of New Mexico Health Sciences Center and Presbyterian Healthcare Services, where he is responsible for medical direction of the molecular diagnostics laboratory. Dr. Williams has acted as principal investigator in several cancer-related Human Leukocyte Antigen (HLA)-focused research studies, and has a special interest in gene expression work related to hepatitis C discovery and study. Exagen's first prognostic reagents for breast cancer use small sets of genes in combination to detect DNA changes, making them more accurate, more practical and more efficient than any other prognostic test currently available to guide treatment of breast cancer patients. The company's next set of prognostic reagents is being developed to identify those patients who may benefit from standard treatment for hepatitis C and to identify patients at risk for development of liver cancer. About Exagen Diagnostics, Inc. As an emerging leader in prognostic testing, Exagen Diagnostics is uniquely able to define small sets of genomic markers that are more accurate than other approaches, whether for breast cancer, infectious disease or other indications. Exagen's proprietary discovery and implementation technologies enable the rapid identification and productization of optimized DNA or RNA genomic marker sets for prognostic or predictive testing, either for diagnostic testing by reference laboratories or for pharmaceutical R&D purposes. For more information, visit www.exagendiagnostics.com.
SOURCE Exagen Diagnostics, Inc.